TargaZyme, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2005-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.targazyme.com
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
Phase 1
- Conditions
- Blood And Marrow TransplantationMyelodysplastic Syndrome (MDS)Transplantation InfectionLeukemiaLymphomaNon-Hodgkin's Lymphoma (NHL)Hodgkin's Lymphoma
- Interventions
- Drug: Fludarabine, Melphalan, ATG (Reduced Intensity)Drug: Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2013-11-18
- Lead Sponsor
- Targazyme, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01983761
- Locations
- 🇺🇸
University Hospitals of Cleveland, Cleveland, Ohio, United States
🇺🇸M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸Scripps Green Hospital, La Jolla, California, United States
© Copyright 2025. All Rights Reserved by MedPath